Yashashree Bethala, MD
Internal Medicine · Biloxi, MSNPI 1659333052
Payments from drug & device makers
Across 103 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$286
- AbbVie$131
- Abbott$102
- Merck$95
- Amgen$95
- GSK$90
- plus $906 from 28 others
What the payments were for
- Food & beverage$1,707100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 17 | $286 |
| AbbVie(2 entities) | 9 | $131 |
| Abbott | 5 | $102 |
| Merck | 7 | $95 |
| Amgen | 6 | $95 |
| GSK | 5 | $90 |
| Novo Nordisk | 5 | $79 |
| Bayer | 4 | $78 |
| AstraZeneca | 5 | $76 |
| Acadia Pharmaceuticals Inc | 3 | $70 |
| Supernus Pharmaceuticals, Inc. | 4 | $63 |
| Johnson & Johnson | 4 | $55 |
| Mylan Specialty L.p. | 2 | $45 |
| Philips North America LLC | 2 | $44 |
| Alnylam Pharmaceuticals Inc. | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Lilly USA, LLC | 2 | $30 |
| Radius Health, Inc. | 2 | $28 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Viatris Specialty LLC | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 2 | $18 |
| Novartis | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Shield Therapeutics Inc | 1 | $15 |
| Seqirus USA Inc | 1 | $15 |
| Gilead | 1 | $15 |
| Corcept Therapeutics | 1 | $15 |
| Bausch Health US, LLC | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
How this compares
$1,707 in reported general payments places this provider in the 70th percentile of 846 internal medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 93 | $112,634 |
| OzempicSemaglutide | 59 | $87,980 |
| EliquisApixaban | 56 | $62,364 |
| XareltoRivaroxaban | 50 | $52,836 |
| FarxigaDapagliflozin Propanediol | 48 | $48,056 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $40,564 |
| TrulicityDulaglutide | 30 | $40,084 |
| JardianceEmpagliflozin | 20 | $31,435 |
| ProliaDenosumab | 17 | $29,421 |
| Repatha SureclickEvolocumab | 25 | $21,430 |
| MounjaroTirzepatide | 11 | $19,541 |
| LinzessLinaclotide | 15 | $17,686 |
| Repatha SyringeEvolocumab | 18 | $17,040 |
| SynthroidLevothyroxine Sodium | 131 | $10,712 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $10,571 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet | $95 | $123,205106 claims |
| Novo NordiskOzempic | $79 | $87,98059 claims |
| PfizerEliquis | $286 | $62,36456 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $30 | $59,62541 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix | $90 | $59,15597 claims |
| Johnson & JohnsonXarelto | $55 | $52,83650 claims |
| AstraZenecaFarxiga | $76 | $48,05648 claims |
| AmgenProlia | $95 | $29,42117 claims |
| AbbVieLinzess, Synthroid | $131 | $28,398146 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Biloxi
- Magdy Gorgi-MikhailBiloxi$157K
- Dawn HansenBiloxi$9K
- James HallBrookhaven$4.8M
- Bob HutchinsJackson$4.6M
- Sidney GortonBelzoni$571K
- David PendleyGulfport$336K
- Sarah KerutJackson$319K
- Gabriel HernandezJackson$196K
- Kelly WilkinsonJackson$183K
- Christina BarlowJackson$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.